The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis

BACKGROUND: There is a growing interest in vortioxetine in major depressive disorder (MDD). OBJECTIVES: This meta-analysis aimed to assess the efficacy and safety of 10 mg/day (mg/d) vortioxetine compared to placebo for MDD in adult. METHODS: Eight randomly controlled trials (RCTs) about the treatment of 10 mg/d vortioxetine in adult patients with MDD were identified and 2354 patients were included in meta-analysis. RESULTS: According to the results, 10 mg/d vortioxetine showed significant differences in response rates (OR=1.88, 95% CI=1.40–2.53, P<0.0001), remission rates (OR=1.54, 95% CI=1.27–1.86, P<0.00001), change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score (SMD=−3.50, 95%CI=−4.83 to −2.17, P<0.00001), clinical global Impression-Global Improvement (CGI-I) total score (SMD=−3.40, 95% CI=−4.69 to −2.11, P<0.00001), and change from baseline in Sheehan Disability Scale (SDS) total score (SMD=−2.09, 95% CI=−2.64 to −1.55, P<0.00001). But 10 mg/d vortioxetine was easier induced nausea (OR=4.18, 95% CI=3.21–5.44, P<0.00001) and constipation (OR=1.88, 95% CI=1.14 to 3.09, P=0.01). CONCLUSION: 10 mg/d vortioxetine was more effective, but easily induced nausea and constipation when compared to placebo for MDD in adult.